Gallbladder Cancer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The gallbladder cancer market size is expected to grow from USD 2.85 billion in 2025 to USD 3.01 billion in 2026 and is forecast to reach USD 3.99 billion by 2031 at 5.75% CAGR over 2026-2031. This report is segmented by Modality (Treatment Type [Chemotherapy and More], Diagnosis [Liver Function Test and More]), Cancer Type (Adenocarcinoma, Squamous Cell Carcinoma, and More), Stage (Stage 0-IV), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Gallbladder Cancer Market Trends and Insights

Increasing Incidence in High-Burden Regions Sustains Structural Demand

Gallbladder cancer incidence is concentrated in distinct geographic areas and has not followed a uniform global pattern. In Chile, evidence links a higher share of Mapuche ancestry to a 3.7% increase in gallbladder cancer mortality risk for each 1% increase in ancestral fraction. This pattern supports screening approaches that reflect population risk rather than applying a single model across all countries. The Gallbladder cancer market, therefore, has a durable patient base in parts of Asia and Latin America where risk factors are concentrated. Population aging in these regions can sustain clinical demand through 2040 without major prevention progress. The Gallbladder cancer market also needs diagnostic capacity that can identify the disease before symptoms appear or become severe.

Adoption of Immunotherapy-Based First-Line Regimens Reshapes Revenue Baseline

Immune checkpoint inhibitors are changing first-line care for advanced biliary tract cancer, including gallbladder cancer. Durvalumab combined with gemcitabine and cisplatin reduced the risk of death by 26% compared with chemotherapy alone in the TOPAZ-1 Phase III study. The 36-month overall survival rate was 14.6% with the combination and 6.9% with chemotherapy alone. The FDA has approved pembrolizumab with chemotherapy for unresectable or metastatic biliary tract cancer, establishing an additional immunotherapy-based option. Adoption remains uneven outside trial settings because treatment selection, reimbursement, and care capacity differ between systems. Longer treatment duration and biosimilar competition for gemcitabine are moving payer attention toward the total cost of each treatment episode.

Late-Stage Diagnosis Caps the Surgically Eligible Population

Late diagnosis remains the main structural limit on curative care in the Gallbladder cancer market. Three-quarters of patients globally present with locally advanced, regionally spread, or metastatic disease, when curative resection is no longer feasible. In the United States, 39.9% to 43.7% of patients presented with serosa invasion or adjacent organ involvement at diagnosis. The 5-year survival rate remained below 5% for most patients, and median overall survival for Stage IV disease was 12.9 months even with current immunochemotherapy. Early disease can resemble gallstone disease, while routine ultrasound can miss subtle lesions. Broad use of AI-assisted screening in high-burden settings would be needed to enlarge the surgically eligible population.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Biomarker-Driven Treatment Opens Addressable Subpopulations
• Advances in Diagnostic Imaging and Molecular Testing Accelerate Early Detection
• High Costs of Advanced Therapies Constrain Uptake in Mid- and Lower-Income Markets

Segment Analysis

Treatment held 75.31% of revenue share by modality in 2025, reflecting the cost and duration of systemic care for advanced disease. Surgery remains the only potentially curative intervention for patients with early-stage disease. Most people with advanced disease receive chemotherapy and immunotherapy combinations as the standard care pathway. Pembrolizumab and durvalumab regimens are being used more widely after U.S. approvals for biliary tract cancer. Targeted therapy use is increasing where molecular testing identifies suitable patients. Zanidatamab gives previously treated HER2-positive disease a specific treatment option. Eligibility for such targeted treatment remains smaller than the overall treatment-seeking population. Intravenous delivery and repeated treatment cycles keep oncology care centered in hospital settings. This treatment profile remains the main source of revenue in the Gallbladder cancer market.

Diagnosis is the fastest-growing modality and is projected to record a 7.25% CAGR from 2026 to 2031. The Gallbladder cancer market size for diagnosis is supported by wider use of AI-enabled CT review, liquid biopsy, and comprehensive genomic profiling. A Chinese multicenter study found that a multimodal deep-learning model achieved a 0.9706 AUC in differentiating malignant from benign gallbladder lesions. Cholangiopancreatography and laparoscopy remain important for staging and deciding whether surgery is possible. Biopsy and histopathology continue to support diagnosis, including testing based on circulating tumor DNA. Liquid biopsy can complement tissue testing when anatomical limitations make sample collection difficult. These approaches can improve the link between diagnosis, staging, and treatment planning. This expansion adds a diagnostic growth path to the Gallbladder cancer market.

Adenocarcinoma accounted for 86.24% of the revenue share by cancer type in 2025. Its leading position aligns with its established histological predominance among biliary malignancies. Major systemic therapies were developed in trial populations that were primarily enriched with adenocarcinoma cases. Squamous cell carcinoma and adenosquamous carcinoma remain smaller parts of the cancer-type distribution. These rarer forms have limited dedicated treatment evidence and historically smaller patient populations. The treatment pathway for these patients has generally relied on broader biliary tract cancer evidence. Better pathology and genomic testing are improving the ability to distinguish rare histological forms. That distinction can make future clinical evidence more specific to each subtype. The Gallbladder cancer market continues to rely on this dominant histology for most treatment demand.

Adenosquamous carcinoma is projected to grow at a 6.22% CAGR through 2031. This pattern reflects improved recognition and classification rather than a confirmed increase in disease prevalence. Next-generation sequencing and standardized pathology reporting can reclassify cases that might previously have been recorded as adenocarcinoma. Molecular research in Chile has identified TP53, TSC2, and NOTCH1 mutations among the leading somatic drivers in local gallbladder cancer cohorts. HER2 amplification is also relevant in a subset of cases and is associated with a treatment option after prior therapy. Population-specific molecular findings may matter in endemic countries with distinct ancestry patterns. Companies seeking regulatory progress in these areas need evidence that reflects local biology. This work may give the Gallbladder cancer market more precise options for rare disease forms.

Complete Report Scope:

• By Modality
  • Treatment Type
    • Surgery
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
    • Supportive Care
  • Diagnosis
    • Liver Function Test
    • Blood Test and Tumor Markers
    • Ultrasound
    • Computed Tomography
    • Magnetic Resonance Imaging
    • Cholangiopancreatography
    • Percutaneous Transhepatic Cholangiography
    • Laparoscopy
    • Biopsy and Histopathology
    • Others
• By Cancer Type
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Adenosquamous Carcinoma
  • Other Cancer Types
• By Stage
  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.61% of the revenue share in 2025. The region benefits from established reimbursement systems, rapid use of immunotherapy combinations, and a series of biliary tract cancer approvals. The United States accounted for the largest regional contribution, with FDA-approved pembrolizumab-based chemotherapy available for unresectable or metastatic disease. Canada had an adoption profile similar to that of the United States. Mexico had growing clinical trial activity that could expand its addressable treatment base. Europe remained an important secondary region, led by Germany, the United Kingdom, and France. The European Commission granted conditional marketing authorization for zanidatamab in July 2025. NICE recommends NHS use of zanidatamab in 2026 for eligible adults after prior systemic therapy.

Asia-Pacific is the fastest-growing region and is projected to advance at a 6.25% CAGR from 2026 to 2031. China and India combine a substantial disease burden with expanding trial activity and growing use of immunotherapy standards. China has reported a rising age-standardized incidence rate, particularly among men, associated with dietary and metabolic risk changes. China’s NMPA approved zanidatamab in May 2025 for previously treated HER2-positive biliary tract cancer. India has high disease incidence in its northeastern regions, where the age-standardized rate reached 14.9 per 100,000 among women. A 2026 Indian randomized trial raised objective response rates from 13.3% to 61.9% by adding nab-paclitaxel to gemcitabine-cisplatin in locally advanced and metastatic disease. Japan and South Korea remain developed treatment settings with molecular profiling and FGFR-directed therapy.

The Middle East, Africa, and South America represented smaller but important parts of the Gallbladder cancer market. Chile and Bolivia continued to record the highest age-standardized death rates for gallbladder and biliary tract cancer. This burden is linked to Mapuche ancestry and gallstone prevalence in indigenous populations. Brazil and Argentina anchor pharmaceutical distribution in South America. Clinical trial participation in Buenos Aires and São Paulo is strengthening evidence for regionally adapted care. GCC countries are investing in tertiary oncology facilities and expanding the availability of immunotherapy combinations. South Africa remains small in absolute size but functions as a reference point for some sub-Saharan African cancer care.

List of Companies Covered in this Report:

• AstraZeneca
• Bayer
• BeiGene, Ltd.
• Boston Scientific
• Bristol-Myers Squibb
• Compass Therapeutics LLC
• Eisai
• Eli Lilly and Company
• Roche
• Incyte
• Intuitive Surgical, Inc.
• Jazz Pharmaceuticals plc
• Johnson & Johnson
• Merck
• Novartis
• Olympus
• Pfizer
• QED Therapeutics Inc.
• Relay Therapeutics, Inc.
• Servier Pharmaceuticals LLC
• Taiho Pharmaceutical Co., Ltd.
• TransThera Sciences Co., Ltd.
• Zymeworks Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support